Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer

被引:10
|
作者
Klein, Florian G. [1 ]
Granier, Charlene [1 ]
Zhao, Yuling [1 ]
Pan, Qi [1 ,3 ]
Tong, Zhichao [1 ,4 ]
Gschwend, Jurgen E. [1 ]
Holm, Per Sonne [1 ,2 ]
Nawroth, Roman [1 ]
机构
[1] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, D-81675 Munich, Germany
[2] Med Univ Innsbruck, Dept Oral & Maxillofacial Surg, A-6020 Innsbruck, Austria
[3] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Urol, Shanghai 200240, Peoples R China
[4] Hosp Harbin Med Univ, Dept Urol, 23 Youzheng St, Harbin 150086, Peoples R China
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 05期
关键词
bladder cancer; combination therapy; Talazoparib; Olaparib; Palbociclib; Retinoblastoma protein; apoptosis; chorioallantoic membrane model; CELL LUNG-CANCER; CDK4/6; INHIBITORS; DNA-DAMAGE; BREAST-CANCER; POLYMERASE INHIBITORS; CLINICAL DEVELOPMENT; CYCLIN D1; REPAIR; PARP; ACTIVATION;
D O I
10.3390/jpm11050340
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecular factors conferring resistance to CDK4/6 inhibition in bladder cancer (BLCA) that also included components within the DNA repair pathway. In this study, we validated whether a combinatory treatment approach of the CDK4/6 inhibitor Palbociclib with Poly-(ADP-Ribose) Polymerase (PARP) inhibitors improves therapy response in BLCA. First, a comparison of PARP inhibitors Talazoparib and Olaparib showed superior efficacy of Talazoparib in vitro and displayed high antitumor activity in xenografts in the chicken chorioallantoic membrane (CAM) model. Moreover, the combination of Talazoparib and the CDK4/6 inhibitor Palbociclib synergistically reduced tumor growth in Retinoblastoma protein (RB)-positive BLCA in vitro and in a CAM model, an effect that relies on Palbociclib-induced cell cycle arrest in G0/G1-phase complemented by a G2 arrest induced by Talazoparib. Interestingly, Talazoparib-induced apoptosis was reduced by Palbociclib. The combination of Palbociclib and Talazoparib effectively enhances BLCA therapy, and RB is a molecular biomarker of response to this treatment regimen.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
    Lee, Cha Len
    Cremona, Mattia
    Farrelly, Angela
    Workman, Julie A.
    Kennedy, Sean
    Aslam, Razia
    Carr, Aoife
    Madden, Stephen
    O'Neill, Brian
    Hennessy, Bryan T.
    Toomey, Sinead
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [42] A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
    Kim, Jung Hoon
    Chang, In Ho
    INVESTIGATIVE AND CLINICAL UROLOGY, 2022, 63 (04) : 373 - 384
  • [43] Manipulation of p53 Protein in Bladder Cancer Treatment
    Mansor, Siti Farizan
    IIUM MEDICAL JOURNAL MALAYSIA, 2021, 20 (01): : 137 - 147
  • [44] Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study
    Masuda, Norikazu
    Nishimura, Reiki
    Takahashi, Masato
    Inoue, Kenichi
    Ohno, Shinji
    Iwata, Hiroji
    Mori, Yuko
    Hashigaki, Satoshi
    Muramatsu, Yasuaki
    Nagasawa, Takashi
    Umeyama, Yoshiko
    Toi, Masakazu
    CANCER SCIENCE, 2018, 109 (03): : 803 - 813
  • [45] Interview for Breast Cancer Management with Dr David Montgomery: marketing authorization for Pfizer's metastatic breast cancer treatment, palbociclib (Ibrance (R)) in combination with endocrine therapy
    Montgomery, David
    Wijayatunga, Roshaine
    BREAST CANCER MANAGEMENT, 2016, 5 (04) : 145 - 150
  • [46] Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment
    Marie-Claude Bourgeois-Daigneault
    Lauren Elizabeth St-Germain
    Dominic Guy Roy
    Adrian Pelin
    Amelia Sadie Aitken
    Rozanne Arulanandam
    Theresa Falls
    Vanessa Garcia
    Jean-Simon Diallo
    John Cameron Bell
    Breast Cancer Research, 18
  • [47] Combination of 2 Bioactive Compounds for Treatment of Breast Cancer: Triterpenoid Cucurbitacin I and Phenolic CAPE
    Karakus, Fuat
    Yilmaz, Kadir
    Eyol, Ergul
    Unuvar, Songul
    NATURAL PRODUCT COMMUNICATIONS, 2019, 14 (06)
  • [48] Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
    Jost, Tina
    Heinzerling, Lucie
    Fietkau, Rainer
    Hecht, Markus
    Distel, Luitpold V.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment
    Bourgeois-Daigneault, Marie-Claude
    St-Germain, Lauren Elizabeth
    Roy, Dominic Guy
    Pelin, Adrian
    Aitken, Amelia Sadie
    Arulanandam, Rozanne
    Falls, Theresa
    Garcia, Vanessa
    Diallo, Jean-Simon
    Bell, John Cameron
    BREAST CANCER RESEARCH, 2016, 18
  • [50] The safety and efficacy of palbociclib in the treatment of metastatic breast cancer
    Ettl, Johannes
    Harbeck, Nadia
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 661 - 668